Examining the impact of changes to diagnostic criteria on Autism Spectrum and Attention Deficit Hyperactivity Disorders

全基因组协会最近发现了影响自闭症谱系和注意缺陷多动障碍(ASD和ADHD)的第一个常见变异，表明增加能力是确定新的治疗靶点和生物标记物的关键。我们试图评估用于诊断ASD和ADHD的标准的变化如何影响症状概况、治疗成本和GWAS结果的推广，以确定这些变化对个性化药物的影响。

Genome-wide association (GWAS) has recently identified the first common variants influencing Autism Spectrum and Attention Deficit Hyperactivity Disorders (ASD and ADHD) demonstrating that increasing power is key to identifying new treatment targets and biomarkers. We seek to assess how changes to the criteria used to diagnose ASD and ADHD affect the symptom profile, cost of treatment and generalisation of GWAS results, to determine the implications of these changes for personalised medicine.